Bristol-Myers Squibb Acquires Amylin Pharmaceuticals and Releases Second Quarter Results
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today reported results for the second quarter of 2012 highlighted by the planned strategic acquisition of Amylin Pharmaceuticals and the presentation of important clinical data from the Company’s immuno-oncology pipeline. The Company also adjusted its GAAP EPS guidance range and confirmed its non-GAAP EPS guidance range for 2012….
